Table 1. Subjects clinical characteristics.
| Subject | Age/sex | Duration, yrs | Skin score | ANA | Organs | Medications |
|---|---|---|---|---|---|---|
| SSc 1 | 41/M | 1 | 43/66 | + | Lung | MTX, omeprazole |
| Speckled | Muscles | Rofecoxib | ||||
| SSc 2 | 54/M | 4 | 30/66 | — | GI | Omeprazole |
| RP | ||||||
| SSc 3 | 62/F | 1 | 33/66 | +1:640 | GI | Nifedipine |
| nucleolar | ||||||
| SSc 4 | 58/F | 2 | 27/66 | +1:640 | Lung | Nifedipine, lansoprazole |
| Speckled | RP, GI |
The clinical data for the four subjects from which skin biopsies were taken are shown. In each case the age, sex, and duration of disease as defined by onset of first non-Raynaud's phenomenon symptoms, modified Rodnam skin scores on a 66-point scale, anti-nuclear antibody (ANA) titers, internal organ involvement, and medication taken by each patient are indicated. The age and sex of normal controls are as follows: Nor1, 39, male; Nor2, 58, female; Nor3, 58, female; and Nor4, 41, female. GI, gastrointestinal tract; RP, Raynaud's phenomenon; MTX, methotrexate; M, male; F, female.